An observational study in Ischemic Stroke, Stroke and Stroke, Acute, sponsored by Chinese University of Hong Kong. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Chinese University of Hong Kong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Ischemic Stroke by Chinese University of Hong Kong — 7 open to participants now, 7 under way, none of them phase 3. Ischemic Stroke · Chinese University of Hong Kong.
Among the 13 studies in Ischemic Stroke by Chinese University of Hong Kong, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2022, is one of 10 observational ones, and was the 10th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →7 of the 13 studies in Ischemic Stroke by Chinese University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 65–80
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–100
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Healthy volunteers
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–80
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 140 across the 3 interventional studies, 224 across the 10 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Ischemic Stroke by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03291652Chinese University of Hong KongMorphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential | 2026-12-23 |
| NCT03295773Chinese University of Hong KongMorphologic Evolution and Remodeling of Intracranial Atherosclerosis: A Longitudinal Study by 3D-rotational Angiography | 2026-12-28 |
| NCT03291392Chinese University of Hong KongCUHK Stroke Biobank | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Ischemic Stroke by Chinese University of Hong Kong, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
As a major breakthrough of acute stroke treatment over the past decade, endovascular thrombectomy (EVT) drastically improved neurological recovery and survival in patients with large vessel occlusion (LVO) ischemic strokes in major clinical trials. Nevertheless, much remained uncertain about the implementation of scientific evidence of EVT into real-world benefits. For instance, healthcare policies that influence critical time-matrices, endovascular thrombectomy techniques that may enhance success rate or prevent complications, or advanced imaging techniques that allow precise prognosis or expansion of treatment populations, should be evaluated. On the other hand, capturing LVO patients who were not able to undergo EVT may reveal the gap between clinical trials and real-world practice in the Asia-Pacific.
In this multicenter prospective collaboration across the Asian-Pacific, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.
In this multicenter, prospective, longitudinal study, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.
The investigators shall recruit patient who are over 18 years of age, with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).
Detailed study procedures are as follows:
After the informed consent, a study identity number will be assigned to each participant. The investigators shall obtain the following data:
Chinese Stroke Population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The investigators shall recruit patients that meet the following inclusion criteria: 1. Patient who are over 18 years of age. 2. Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).
Diagnostic Test: Thrombus analyses · Diagnostic Test: Imaging assessment
Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
Pre-morbid functional status assessed by modified Rankin Scale (mRS)
Neurological recover and survival as assessed by mRS at 90 days, with the scale runs from 0-6, running from perfect health without symptoms (Score 0) to death (Score 6).
Time frame: 18 October 2032
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Oct 2032, 119 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 119 months is above that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →